Macrophage Cell Membrane Camouflaged Mesoporous Silica Nanocapsules for In Vivo Cancer Therapy

2015 ◽  
Vol 4 (11) ◽  
pp. 1645-1652 ◽  
Author(s):  
Minjun Xuan ◽  
Jingxin Shao ◽  
Luru Dai ◽  
Qiang He ◽  
Junbai Li
Keyword(s):  
Cancer Therapy ◽  
Cell Membrane ◽  
Mesoporous Silica ◽  
Macrophage Cell ◽  
Silica Nanocapsules

scholarly journals Current Stimuli-Responsive Mesoporous Silica Nanoparticles for Cancer Therapy

Pharmaceutics ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 71
Author(s):  
Thashini Moodley ◽  
Moganavelli Singh
Keyword(s):  
Cancer Therapy ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Therapeutic Agents ◽  
Metal Species ◽  
Stimuli Responsive ◽  
Combination Drug ◽  
Incidence And Mortality

With increasing incidence and mortality rates, cancer remains one of the most devastating global non-communicable diseases. Restricted dosages and decreased bioavailability, often results in lower therapeutic outcomes, triggering the development of resistance to conventionally used drug/gene therapeutics. The development of novel therapeutic strategies using multimodal nanotechnology to enhance specificity, increase bioavailability and biostability of therapeutics with favorable outcomes is critical. Gated vectors that respond to endogenous or exogenous stimuli, and promote targeted tumor delivery without prematurely cargo loss are ideal. Mesoporous silica nanoparticles (MSNs) are effective delivery systems for a variety of therapeutic agents in cancer therapy. MSNs possess a rigid framework and large surface area that can incorporate supramolecular constructs and varying metal species that allow for stimuli-responsive controlled release functions. Its high interior loading capacity can incorporate combination drug/gene therapeutic agents, conferring increased bioavailability and biostability of the therapeutic cargo. Significant advances in the engineering of MSNs structural and physiochemical characteristics have since seen the development of nanodevices with promising in vivo potential. In this review, current trends of multimodal MSNs being developed and their use in stimuli-responsive passive and active targeting in cancer therapy will be discussed, focusing on light, redox, pH, and temperature stimuli.

Uniform hollow mesoporous silica nanocages for drug delivery in vitro and in vivo for liver cancer therapy

2011 ◽  
Vol 21 (14) ◽  
pp. 5299 ◽  
Author(s):  
Tingting Wang ◽  
Fang Chai ◽  
Qin Fu ◽  
Lingyu Zhang ◽  
Haiyan Liu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Liver Cancer ◽  
Mesoporous Silica ◽  
Hollow Mesoporous Silica

Macrophage cell tracking PET imaging using mesoporous silica nanoparticles via in vivo bioorthogonal F-18 labeling

Biomaterials ◽  
2019 ◽  
Vol 199 ◽  
pp. 32-39 ◽  
Author(s):  
Hyeon Jin Jeong ◽  
Ran Ji Yoo ◽  
Jin Kwan Kim ◽  
Min Hwan Kim ◽  
Su Hong Park ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Pet Imaging ◽  
Cell Tracking ◽  
Mesoporous Silica Nanoparticles ◽  
Macrophage Cell

scholarly journals Cancer Cell Membrane Decorated Silica Nanoparticle Loaded with miR495 and Doxorubicin to Overcome Drug Resistance for Effective Lung Cancer Therapy

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Jinyuan He ◽  
Chulian Gong ◽  
Jie Qin ◽  
Mingan Li ◽  
Shaohong Huang
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Cell Membrane ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Silica Nanoparticle ◽  
Glycoprotein P ◽  
Lung Cancer Therapy

Abstract Current cancer therapy usually succumbs to many extracellular and intracellular barriers, among which untargeted distribution and multidrug resistance (MDR) are two important difficulties responsible for poor outcome of many drug delivery systems (DDS). Here, in our study, the dilemma was addressed by developing a cancer cell membrane (CCM)-coated silica (SLI) nanoparticles to co-deliver miR495 with doxorubicin (DOX) for effective therapy of lung cancer (CCM/SLI/R-D). The homologous CCM from MDR lung cancer cells (A549/DOX) was supposed to increase the tumor-homing property of the DDS to bypass the extracellular barriers. Moreover, the MDR of cancer cells were conquered through downregulation of P-glycoprotein (P-gp) expression using miR495. It was proved that miR495 could significantly decrease the expression of P-gp which elevated intracellular drug accumulation in A549/DOX. The in vitro and in vivo results exhibited that CCM/SLI/R-D showed a greatly enhanced therapeutic effect on A549/DOX, which was superior than applying miR495 or DOX alone. The preferable effect of CCM/SLI/R-D on conquering the MDR in lung cancer provides a novel alternative for effective chemotherapy of MDR cancers.

scholarly journals Mesoporous Silica Nanoparticles for Dual-Mode Chemo-Sonodynamic Therapy by Low-Energy Ultrasound

Materials ◽  
2018 ◽  
Vol 11 (10) ◽  
pp. 2041 ◽  
Author(s):  
Jingjing Wang ◽  
Yajing Jiao ◽  
Yiran Shao
Keyword(s):  
Cancer Therapy ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Low Energy ◽  
Dual Mode ◽  
Sonodynamic Therapy ◽  
Internal Channel ◽  
Cavitation Effect

Low-energy ultrasound (LEUS), exhibiting obvious advantages as a safe therapeutic strategy, would be promising for cancer therapy. We had synthesized a LEUS-responsive targeted drug delivery system based on functional mesoporous silica nanoparticle for cancer therapy. Paclitaxel (PTX) was loaded in mesoporous silica nanoparticles with a hydrophobic internal channel, and folic acid (FA) functionalized β-Cyclodextrin (β-CD) was capped on the surface of the nanoparticles (DESN), which acted as a cancer-targeting moiety and solubilizer. The existence of a hydrophobic internal channel in the DESN was beneficial to the storage of hydrophobic PTX, along with the enhancement of the cavitation effect produced by mild low-energy ultrasound (LEUS, ≤1.0 W/cm2, 1 MHz). The DESN showed significantly enhanced cavitation effect, selective targeting, and achieved a rapid drug release under mild LEUS. To investigate the in vivo antitumor efficacy of the DESN upon LEUS irradiation, we established a 4T1 mammary tumor model. The DESN were confirmed to be of great biodegradability/biocompatibility. The tumor growth was significantly inhibited when the mice were treated with DESN (10 mg/kg) + LEUS with the relative tumor volume reduced to 4.72 ± 0.70 compared with the control group (V/V0 = 17.12 ± 2.75). The DESN with LEUS represented excellent inhibiting effect on tumor cell in vivo. This work demonstrated that DESN mediating dual mode chemo-sonodynamic therapy could be triggered by extracorporeal remote control, may suggest a promising clinical application in cancer therapy.

scholarly journals Enhancing the Effectiveness of Drug-based Cancer Therapy by Electroporation (Electropermeabilization)

2002 ◽  
Vol 1 (1) ◽  
pp. 71-82 ◽  
Author(s):  
Dietmar P. Rabussay ◽  
Gurvinder S. Nanda ◽  
Paul M. Goldfarb
Keyword(s):  
Cancer Therapy ◽  
Cell Membrane ◽  
Field Strength ◽  
Head And Neck ◽  
Blood Vessels ◽  
Tumor Cells ◽  
Tumor Tissue ◽  
Tumor Response ◽  
Efficient Access

Many conventional chemotherapeutic drugs, as well as DNA for cancer gene therapy, require efficient access to the cells' interior to be effective. The cell membrane is a formidable barrier to many of these drugs, including therapeutic DNA constructs. Electropermeabilization (EP, often used synonymously with “electroporation”) has become a useful method to temporarily increase the permeability of the cell membrane, allowing a broad variety of molecules efficient access to the cell interior. EP is achieved by the application of short electrical pulses of relatively high local field strength to the target tissue of choice. In cancer therapy, EP can be applied in vivo directly to the tumor to be treated, in order to enhance intracellular uptake of drugs or DNA. Alternatively, EP can be used to deliver DNA into cells of healthy tissue to achieve longer-lasting expression of cancer-suppressing genes. In addition, EP has been used in ex vivo therapeutic approaches for the transfection of a variety of cells in suspension. In this paper, we communicate results related to the development of a treatment for squamous cell carcinomas of the head and neck, using electropermeabilization to deliver the drug bleomycin in vivo directly into the tumor cells. This drug, which is not particularly effective as a conventional therapeutic, becomes highly potent when the intracellular concentration is enhanced by EP treatment. In animal model experiments we found a drug dose of 1 U/cm3 tumor tissue (delivered in 0.25 mL of an aqueous solution/cm3 tumor tissue) and an electrical field strength of 750 V/cm or higher to be optimal for the treatment of human squamous cell tumors grown subcutaneously in mice. Within 24–48 hours, the majority of tumor cells are rapidly destroyed by this bleomycin-electroporation therapy (B-EPT). This raises the concern that healthy tissue may be similarly affected. In studies with large animals we showed that normal muscle and skin tissue, normal tissue surrounding major blood vessels and nerves, as well as healthy blood vessels and nerves themselves, are much less affected than tumor tissue. Normal tissues did show acute, focal, and transitory effects after treatment, but these effects are relatively minor under standard treatment conditions. The severity of these effects increases with the number of electric pulse cycles and applied voltage. The observed histological changes resolved 20 to 40 days after treatment or sooner, even after excessive EP treatment. Thus, B-EPT is distinct from other ablative therapies, such as thermal, cryo, or photodynamic ablation, which equally affect healthy and tumor tissue. In comparison to surgical or radiation therapy, B-EPT also has potential as a tissue-sparing and function-preserving therapy. In clinical studies with over 50 late stage head and neck cancer patients, objective tumor response rates of 55–58%, and complete tumor response rates of 19–30% have been achieved.

Macrophage Cell Membrane Camouflaged Au Nanoshells for in Vivo Prolonged Circulation Life and Enhanced Cancer Photothermal Therapy

2016 ◽  
Vol 8 (15) ◽  
pp. 9610-9618 ◽  
Author(s):  
Mingjun Xuan ◽  
Jingxin Shao ◽  
Luru Dai ◽  
Junbai Li ◽  
Qiang He
Keyword(s):  
Cell Membrane ◽  
Photothermal Therapy ◽  
Macrophage Cell

scholarly journals Ruthenium-loaded mesoporous silica as tumor microenvironment-response nano-fenton reactors for precise cancer therapy

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Dongdong Sun ◽  
Zekun Wang ◽  
Pu Zhang ◽  
Chenyang Yin ◽  
Jingyuan Wang ◽  
...  
Keyword(s):  
Side Effects ◽  
Tumor Microenvironment ◽  
Cancer Therapy ◽  
Mesoporous Silica ◽  
Cancer Cells ◽  
Rational Design ◽  
Human Cancer ◽  
Release Mechanism ◽  
Tumor Xenografts

Abstract Background Nano-Fenton reactors as novel strategy to selectively convert hydrogen peroxide (H2O2) into active hydroxyl radicals in tumor microenvironment for cancer therapy had attracted much attention. However, side effects and low efficiency remain the main drawbacks for cancer precise therapy. Results Here, ruthenium-loaded palmitoyl ascorbate (PA)-modified mesoporous silica (Ru@SiO2-PA) was successfully fabricated and characterized. The results indicated that Ru@SiO2-PA under pH6.0 environment displayed enhanced growth inhibition against human cancer cells than that of pH7.4, which indicated the super selectivity between cancer cells and normal cells. Ru@SiO2-PA also induced enhanced cancer cells apoptosis, followed by caspase-3 activation and cytochrome-c release. Mechanism investigation revealed that Ru@SiO2-PA caused enhanced generation of superoxide anion, which subsequently triggered DNA damage and dysfunction of MAPKs and PI3K/AKT pathways. Moreover, Ru@SiO2-PA effectively inhibited tumor spheroids and tumor xenografts growth in vivo by induction of apoptosis. The real-time imaging by monitoring Ru fluorescence in vitro and in vivo revealed that Ru@SiO2-PA mainly accumulated in cell nucleus and tumor xenografts. Importantly, Ru@SiO2-PA showed no side effects in vivo, predicting the safety and potential application in clinic. Conclusions Our findings validated the rational design that Ru@SiO2-PA can act as novel tumor microenvironment-response nano-Fenton reactors for cancer precise therapy. Graphic Abstract

Sign in / Sign up

Export Citation Format

Share Document